Opportunities for expanding clinical trial enrollment for relapsed and refractory pediatric acute myeloid leukemia in the United States and Canada

Pediatr Blood Cancer. 2017 Nov;64(11). doi: 10.1002/pbc.26632. Epub 2017 May 16.

Authors

Thomas B Alexander^{1

2}, Nickhill Bhakta³, E Anders Kolb⁴, Jeffrey E Rubnitz¹

Affiliations

¹ Departments of Oncology, St. Jude Children's Research Hospital, Memphis, Tennessee.
² Department of Pediatrics, University of North Carolina, Chapel Hill, North Carolina.
³ Global Pediatric Medicine, St. Jude Children's Research Hospital, Memphis, Tennessee.
⁴ Nemours/Alfred I. duPont Hospital for Children, Wilmington, Delaware.

PMID: 28509405
DOI: 10.1002/pbc.26632

No abstract available

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Canada
Child
Clinical Trials as Topic*
Drug Resistance, Neoplasm
Female
Humans
Leukemia, Myeloid, Acute / therapy*
Male
Neoplasm Recurrence, Local / therapy
Patient Selection*
United States